Access to personalised oncology in Europe

The development of personalised oncology (PO), where the right treatment is given to the right person at the right time determined by the use of biomarkers (a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process or of a condition or disease), is predicted to lead to better outcomes and reduced risk of side effects for patients with cancer as well as reducing costs and improving efficiencies of healthcare systems. The European Federation of Pharmaceutical Industries and Associations (EFPIA) asked MTRG to conduct an evidence-based analysis to determine the use of personalised oncology products across Europe and to highlight barriers affecting patient access. The ultimate aim is for evidence highlighted in the report to be used to initiate discussions with policy-makers to work towards enhancing access to effective treatments and improving cancer-based health outcomes across Europe.